JP2023503769A5 - - Google Patents

Info

Publication number
JP2023503769A5
JP2023503769A5 JP2022515083A JP2022515083A JP2023503769A5 JP 2023503769 A5 JP2023503769 A5 JP 2023503769A5 JP 2022515083 A JP2022515083 A JP 2022515083A JP 2022515083 A JP2022515083 A JP 2022515083A JP 2023503769 A5 JP2023503769 A5 JP 2023503769A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
weight
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503769A (ja
JP7822308B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000745 external-priority patent/WO2021048626A1/en
Publication of JP2023503769A publication Critical patent/JP2023503769A/ja
Publication of JP2023503769A5 publication Critical patent/JP2023503769A5/ja
Application granted granted Critical
Publication of JP7822308B2 publication Critical patent/JP7822308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515083A 2019-09-15 2020-09-14 固形腫瘍の処置のための組成物 Active JP7822308B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900557P 2019-09-15 2019-09-15
PCT/IB2020/000745 WO2021048626A1 (en) 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors

Publications (3)

Publication Number Publication Date
JP2023503769A JP2023503769A (ja) 2023-02-01
JP2023503769A5 true JP2023503769A5 (cg-RX-API-DMAC10.html) 2023-09-04
JP7822308B2 JP7822308B2 (ja) 2026-03-02

Family

ID=74866186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515083A Active JP7822308B2 (ja) 2019-09-15 2020-09-14 固形腫瘍の処置のための組成物

Country Status (7)

Country Link
US (1) US20220323411A1 (cg-RX-API-DMAC10.html)
EP (1) EP4031130A4 (cg-RX-API-DMAC10.html)
JP (1) JP7822308B2 (cg-RX-API-DMAC10.html)
CN (1) CN115066241A (cg-RX-API-DMAC10.html)
AU (1) AU2020347539B2 (cg-RX-API-DMAC10.html)
IL (1) IL291351B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021048626A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative
WO2024100533A1 (en) * 2022-11-07 2024-05-16 Raziel Therapeutics Ltd. Crystalline carbazole derivative and methods of making thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
AU2021213469B2 (en) * 2020-01-28 2026-06-04 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma

Similar Documents

Publication Publication Date Title
JP7232796B2 (ja) 第viii因子両性イオンポリマーコンジュゲート
AU2019356168B2 (en) Imaging agents
JP2025510074A5 (cg-RX-API-DMAC10.html)
JP6162112B2 (ja) 制御された放出システム
JP2021501754A5 (cg-RX-API-DMAC10.html)
JP2021522275A5 (cg-RX-API-DMAC10.html)
JP2022533069A5 (cg-RX-API-DMAC10.html)
BR112012014556B1 (pt) Polímero multifuncional conjugado zwiteriônico
AU2018355222B2 (en) Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)
JP2012528240A5 (cg-RX-API-DMAC10.html)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2023510865A5 (cg-RX-API-DMAC10.html)
RU2017122824A (ru) Пирролопиримидиновое соединение
AR010743A1 (es) Compuestos de pirazol, utiles como inhibidores de la liberacion de acidos grasos mediada por la fosfolipasa a2 secretora no pancreatica humana.procedimientos para preparar dichos compuestos y composiciones farmaceuticas formuladas con dichos compuestos
RU2014154009A (ru) Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
JP2023512206A5 (cg-RX-API-DMAC10.html)
JP2021517164A5 (cg-RX-API-DMAC10.html)
JP2024545787A5 (cg-RX-API-DMAC10.html)
JP2022554094A5 (cg-RX-API-DMAC10.html)
JP2022546110A5 (cg-RX-API-DMAC10.html)
CN108601952A (zh) 雷公藤内酯的葡萄糖缀合物、类似物及其用途
JP2023512227A5 (cg-RX-API-DMAC10.html)
JP2025508331A5 (cg-RX-API-DMAC10.html)
JP2007505044A5 (cg-RX-API-DMAC10.html)
JP2022550174A5 (cg-RX-API-DMAC10.html)